Compare Stocks: RNA, SGMT, IRWD, and MDXG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRWD Ironwood Pharmaceuticals	$4.36 +3.1%	$4.13	$1.26 ▼ $5.78	$720.45M	0.2	1.49 million shs	7.69 million shs
MDXG MiMedx Group	$4.77 +1.7%	$4.38	$3.03 ▼ $7.97	$695.28M	1.43	917,603 shs	3.90 million shs
RNA Avidity Biosciences	$8.95 -6.4%	$12.18	$8.66 ▼ $16.77	$153.10M	N/A	307,747 shs	1.04 million shs
SGMT Sagimet Biosciences	$11.09 -0.7%	$9.33	$4.50 ▼ $11.45	$689.34M	3.45	898,921 shs	1.85 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRWD Ironwood Pharmaceuticals	0.00%	+6.86%	+5.31%	+23.16%	+240.63%
MDXG MiMedx Group	0.00%	+4.38%	+10.93%	+29.44%	-31.27%
RNA Avidity Biosciences	0.00%	-13.61%	-33.61%	-29.30%	-77.66%
SGMT Sagimet Biosciences	0.00%	+1.93%	+8.94%	+66.02%	+80.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRWD Ironwood Pharmaceuticals	$4.36 +3.1%	$4.13	$1.26 ▼ $5.78	$720.45M	0.2	1.49 million shs	7.69 million shs
MDXG MiMedx Group	$4.77 +1.7%	$4.38	$3.03 ▼ $7.97	$695.28M	1.43	917,603 shs	3.90 million shs
RNA Avidity Biosciences	$8.95 -6.4%	$12.18	$8.66 ▼ $16.77	$153.10M	N/A	307,747 shs	1.04 million shs
SGMT Sagimet Biosciences	$11.09 -0.7%	$9.33	$4.50 ▼ $11.45	$689.34M	3.45	898,921 shs	1.85 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRWD Ironwood Pharmaceuticals	0.00%	+6.86%	+5.31%	+23.16%	+240.63%
MDXG MiMedx Group	0.00%	+4.38%	+10.93%	+29.44%	-31.27%
RNA Avidity Biosciences	0.00%	-13.61%	-33.61%	-29.30%	-77.66%
SGMT Sagimet Biosciences	0.00%	+1.93%	+8.94%	+66.02%	+80.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRWD Ironwood Pharmaceuticals	2.57	Moderate Buy	$6.23	42.97% Upside
MDXG MiMedx Group	2.71	Moderate Buy	$8.57	79.69% Upside
RNA Avidity Biosciences	2.25	Hold	$63.75	612.29% Upside
SGMT Sagimet Biosciences	2.73	Moderate Buy	$27.96	152.11% Upside

Current Analyst Ratings Breakdown

Latest RNA, SGMT, IRWD, and MDXG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2026	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/9/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.71
9/9/2026	SGMT Sagimet Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$8.00 ➝ $18.00
9/9/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.71
9/4/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/27/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/27/2026	MDXG MiMedx Group	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$6.00 ➝ $8.00
8/25/2026	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$29.00
8/21/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C+)
8/17/2026	MDXG MiMedx Group	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$8.00
8/17/2026	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRWD Ironwood Pharmaceuticals	$296.15M	2.43	$0.26 per share	16.94	($1.61) per share	-2.71
MDXG MiMedx Group	$418.63M	1.66	$0.55 per share	8.61	$1.73 per share	2.76
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	$2M	344.68	N/A	N/A	$3.42 per share	3.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	5.66	N/A	N/A	33.36%	-58.38%	34.93%	11/9/2026 (Estimated)
MDXG MiMedx Group	$48.58M	$0.04	119.28	28.06	N/A	1.76%	12.09%	9.22%	11/4/2026 (Estimated)
RNA Avidity Biosciences	N/A	-$2.15	N/A	N/A	N/A	N/A	N/A	N/A	11/12/2026 (Estimated)
SGMT Sagimet Biosciences	-$51.04M	-$1.28	N/A	N/A	N/A	N/A	-31.96%	-30.57%	11/12/2026 (Estimated)

Latest RNA, SGMT, IRWD, and MDXG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	RNA Avidity Biosciences	-$1.42	-$1.18	+$0.24	-$1.18	$0.67 million	$3.00 million
8/11/2026	Q2 2026	SGMT Sagimet Biosciences	-$0.2510	-$0.26	-$0.0090	-$0.26	N/A	N/A
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRWD Ironwood Pharmaceuticals	N/A	6.06	6.06
MDXG MiMedx Group	0.07	5.33	4.79
RNA Avidity Biosciences	N/A	8.73	8.73
SGMT Sagimet Biosciences	N/A	45.03	45.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRWD Ironwood Pharmaceuticals	N/A
MDXG MiMedx Group	79.15%
RNA Avidity Biosciences	N/A
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
IRWD Ironwood Pharmaceuticals	9.30%
MDXG MiMedx Group	2.50%
RNA Avidity Biosciences	3.83%
SGMT Sagimet Biosciences	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRWD Ironwood Pharmaceuticals	100	165.24 million	149.87 million	Optionable
MDXG MiMedx Group	808	145.76 million	142.12 million	Optionable
RNA Avidity Biosciences	190	17.11 million	16.45 million	Optionable
SGMT Sagimet Biosciences	16	62.16 million	55.01 million	Optionable

RNA, SGMT, IRWD, and MDXG Headlines

Recent News About These Companies

Sagimet Biosciences (NASDAQ:SGMT) Research Coverage Started at Cantor Fitzgerald

September 12, 2026 | americanbankingnews.com

Sagimet Biosciences (NASDAQ:SGMT) Reaches New 1-Year High - Here's What Happened

September 11, 2026 | americanbankingnews.com

Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 4.1% - Time to Buy?

September 10, 2026 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Upgraded at Cantor Fitzgerald

September 10, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $1.55 Million in Sagimet Biosciences Inc. $SGMT

September 10, 2026 | marketbeat.com

Cantor Fitzgerald initiates coverage of Sagimet Biosciences at overweight

September 9, 2026 | msn.com

Barclays upgrades Sagimet Biosciences to overweight from equal-weight

September 9, 2026 | msn.com

Sagimet Biosciences (NASDAQ:SGMT) Hits New 52-Week High - Here's Why

September 9, 2026 | marketbeat.com

Seven Fleet Capital Management LP Buys Shares of 403,545 Sagimet Biosciences Inc. $SGMT

September 5, 2026 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Sets New 1-Year High - Should You Buy?

September 3, 2026 | marketbeat.com

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from Analysts

August 31, 2026 | marketbeat.com

Sagimet Biosciences' (SGMT) Buy Rating Reiterated at HC Wainwright

August 25, 2026 | marketbeat.com

Sagimet Biosciences Announces AURORA Phase 3 Acne Trial on Track to Begin Enrollment in Q4 2026

August 25, 2026 | quiverquant.comQ

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

August 25, 2026 | globenewswire.com

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2026 | markets.businessinsider.com

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2026 | globenewswire.com

FDA Approves Sagimet Biosciences' IND for Phase 3 Denifanstat Acne Study

August 14, 2026 | kalkinemedia.comK

Sagimet Biosciences Receives US FDA Clearance for Phase 3 Acne Trial

August 13, 2026 | finance.yahoo.com

Sagimet higher on FDA clearance of late-stage acne trial

August 13, 2026 | msn.com

Sagimet Biosciences Inc.: Sagimet Biosciences Receives FDA "Study May Proceed" Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

August 13, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RNA, SGMT, IRWD, and MDXG Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

$4.36 +0.13 (+3.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.35 -0.01 (-0.23%)

As of 09/18/2026 07:53 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

MiMedx Group NASDAQ:MDXG

$4.77 +0.08 (+1.71%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.78 +0.01 (+0.13%)

As of 09/18/2026 07:56 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Avidity Biosciences NASDAQ:RNA

$8.95 -0.61 (-6.38%)

As of 09/18/2026 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Sagimet Biosciences NASDAQ:SGMT

$11.09 -0.08 (-0.72%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$11.05 -0.04 (-0.36%)

As of 09/18/2026 07:51 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNA, SGMT, IRWD, and MDXG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNA, SGMT, IRWD, and MDXG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNA, SGMT, IRWD, and MDXG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RNA, SGMT, IRWD, and MDXG Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

MiMedx Group NASDAQ:MDXG

Avidity Biosciences NASDAQ:RNA

Sagimet Biosciences NASDAQ:SGMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNA, SGMT, IRWD, and MDXG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNA, SGMT, IRWD, and MDXG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNA, SGMT, IRWD, and MDXG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RNA, SGMT, IRWD, and MDXG Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

MiMedx Group NASDAQ:MDXG

Avidity Biosciences NASDAQ:RNA

Sagimet Biosciences NASDAQ:SGMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools